Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)
The objectives of this study are to assess safety and efficacy of Imfinzi (durvalumab) in a real world setting in patients treated with Imfinzi under the approved indication in Korea.
Lung Cancer, Biliary Tract Cancer
Safety (AE, SAE, ADR, SADR, AESI, DAE, fatal AE), safety outcome, for up to 1 year after the first dose of Imfinzi|Dose interruptions, Safety outcome, for up to 1 year after the first dose of Imfinzi|Duration of treatment, Safety outcome, for up to 1 year after the first dose of Imfinzi
Progression free survival (PFS), efficacy outcome, for up to 1 year after the first dose of Imfinzi|Objective response rate (ORR), efficacy outcome, for up to 1 year after the first dose of Imfinzi|Duration of response (DoR), efficacy outcome, for up to 1 year after the first dose of Imfinzi
Primary objective : To assess safety of Imfinzi for patients treated with Imfinzi under the approved indication in Korea

Outcome Measure:

* Safety (adverse event (AE), serious adverse events (SAE), adverse drug reaction (ADR), serious adverse drug reaction (SADR), adverse events of special interest (AESI), adverse events leading to discontinuation (DAE), and adverse events leading to deaths (fatal AE))
* Dose interruptions
* Duration of treatment
* Reason for treatment discontinuation Secondary objective: To assess efficacy of Imfinzi for patients treated with Imfinzi under the approved indication in Korea

Outcome Measure:

* Progression free survival (PFS)
* Objective response rate (ORR)
* Duration of response (DoR)